325 related articles for article (PubMed ID: 23417352)
21. Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.
Lobo ED; Heathman M; Kuan HY; Reddy S; O'Brien L; Gonzales C; Skinner M; Knadler MP
Clin Pharmacokinet; 2010 May; 49(5):311-21. PubMed ID: 20384393
[TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE; Nicholls AJ; Kamm BR
Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
[TBL] [Abstract][Full Text] [Related]
23. Vilazodone: a new treatment option for major depressive disorder.
Owen RT
Drugs Today (Barc); 2011 Jul; 47(7):531-7. PubMed ID: 22013560
[TBL] [Abstract][Full Text] [Related]
24. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
[TBL] [Abstract][Full Text] [Related]
25. Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder.
Guay DR
Consult Pharm; 2012 Dec; 27(12):857-67. PubMed ID: 23229074
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects.
Tianmei S; Knadler MP; Lim MT; Yeo KP; Teng L; Liang S; Pan AX; Lobo ED
Clin Pharmacokinet; 2007; 46(9):767-75. PubMed ID: 17713974
[TBL] [Abstract][Full Text] [Related]
27. Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?
Phelan M; Anzures-Cabrera J; Carlile DJ; Rowell L; Kuhlmann O; Arold G; Robson R; Bentley D
Clin Pharmacokinet; 2013 Apr; 52(4):255-65. PubMed ID: 23400900
[TBL] [Abstract][Full Text] [Related]
28. Vilazodone (Viibryd)--a new antidepressant.
Med Lett Drugs Ther; 2011 Jul; 53(1368):53-4. PubMed ID: 21738107
[TBL] [Abstract][Full Text] [Related]
29. Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib.
Small DS; Zhang W; Royalty J; Cannady EA; Downs D; Ortega D; Suico JG
Eur J Clin Pharmacol; 2016 May; 72(5):563-72. PubMed ID: 26857125
[TBL] [Abstract][Full Text] [Related]
30. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder.
Robinson DS; Kajdasz DK; Gallipoli S; Whalen H; Wamil A; Reed CR
J Clin Psychopharmacol; 2011 Oct; 31(5):643-6. PubMed ID: 21869687
[TBL] [Abstract][Full Text] [Related]
31. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
Rolfo C; de Vos-Geelen J; Isambert N; Molife LR; Schellens JHM; De Grève J; Dirix L; Grundtvig-Sørensen P; Jerusalem G; Leunen K; Mau-Sørensen M; Plummer R; Learoyd M; Bannister W; Fielding A; Ravaud A
Clin Pharmacokinet; 2019 Sep; 58(9):1165-1174. PubMed ID: 30877569
[TBL] [Abstract][Full Text] [Related]
34. Vilazodone for the treatment of depression.
Lindsey WT
Ann Pharmacother; 2011 Jul; 45(7-8):946-53. PubMed ID: 21672888
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.
Dimmitt DC; Shah AK; Arumugham T; Cramer MB; Halstenson C; Horton M; Weir SJ
J Clin Pharmacol; 1998 Sep; 38(9):798-806. PubMed ID: 9753207
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
[TBL] [Abstract][Full Text] [Related]
37. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects.
Chu NN; Chen WL; Xu HR; Li XN
Clin Drug Investig; 2012 Dec; 32(12):791-8. PubMed ID: 23109219
[TBL] [Abstract][Full Text] [Related]
39. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
[TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
